Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1198 - Rapid genetic screening experience among endometrial cancer about Lynch syndrome by surgeon


18 Dec 2016


Poster lunch


Min Kyu Kim


Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585


M.K. Kim

Author affiliations

  • Obstetrics And Gynecology, Samsung Changwon Hospital Sung Kyun Kwan University, 630-723 - Changwon/KR


Abstract 1198


Lynch syndrome increase risk of mostly endometrial cancer and colorectal cancer. There is not much study about detecting algorithm among Korean population by gynecologic oncology surgeon. We undertook this study to investigate this.


A retrospective review of endometrial cancer patients who was counseled about Lynch syndrome in Department of Obstetrics and gynecology, Samsung Changwon Hospital by single surgeon was done. Clinical information was extracted from the medical record including age, family and personal history of cancer, immunohistochemistry(IHC), microsatellite instability test(MSI), and gene sequencing results. Risk management and posttest education after result were offered about risk reducing options and cascade testing for affected individual


Total test was 16.There were two germline mutations (both MSH2) (c.23C>T (p.Thr8Met), c.187delG (p.Val63*).Both were negative for MSH2 IHC, But no patient matched criteria of Amsterdam. Four variation of unknown significance (VUS) was found (Three MSH2 and One MLH1).Among those all were abnormal in IHC and there was only one Amsterdam criteria matched patient. There were two unstable MSI patients, one was MSH2 germline mutation and the other was MSH2 VUS. Median age was 57(41∼76).Most cases were endometrioid type (11/16, 69%).Seventy five percent were stage I(12/16).


We found two MSH2 germline mutation patients among this population. Gynecologic oncology surgeon can be adapted to develop the ability to assess and evaluate genetic risk among endometrial cancer.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings